Captopril (Capoten) hasbeen evaluated in the treatment both of hypertension and cardiac
failure (Atkinson & Robertson, 1979). However, it is currently indicated only for severe or …

1 The long‐term effect of the converting‐enzyme inhibitor captopril was investigated in 76
patients with various forms of severe hypertension, most cases being resistant to a …

1 The ability of captopril, 150 mg three times daily by mouth, to effect sustained reduction in
plasma angiotensin II, with converse increases in circulating angiotensin I, and in active …

Abstract Captopril (1 and 4 mg/kg) was administered intravenously to rabbits and plasma
converting enzyme measured using a radioenzymatic technique. Captopril inhibited plasma …

The converting-enzyme inhibitor, Captopril, was given to ten patients with refractory severe
hypertension of renal origin: 6 patients had chronic renal failure, 3 patients had hypertension …

Blood concentration and urinary excretion of captopril following 50 mg oral administration
were determined by high-performance liquid chromatography in normal subjects and …

Captopril (SQ 14225) is a competitive inhibitor of converting enzyme. We are currently
comparing the efficacy of Captopril with propranolol in patients with mild to moderate WHO …

The new orally active angiotensin-converting enzyme inhibitor captopril (Squibb, SQ 14225)
is effective in hypertension whether or not of renal origin.'Rashes may occur butresolve …

The introduction of captopril-the first orally active inhibitor of angiotensin converting enzyme-
into clinical medicine has been an example of skilled, purposeful pharmacological …

The kinetics of captopril plasma levels and of the drug‐induced plasma converting enzyme
activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) …